Anticoagulation Bridging Decision Before Procedure
A 70-year-old man with atrial fibrillation (CHA2DS2-VASc 5) on apixaban 5 mg BID and a mechanical mitral valve (he also takes warfarin? No - he is on apixaban only, which is a problem in itself) is scheduled for a colonoscopy with possible polypectomy in 5 days. He has a history of GI bleeding 3 years ago. His creatinine clearance is 55 mL/min. The gastroenterologist asks whether to stop apixaban, bridge with enoxaparin, and when to restart. The patient is anxious about stroke and wants 'full blood thinning' throughout.
1. Identify the safety problem with this patient's current anticoagulant and explain the bridging question for this procedure.
Read the worked answer
Critical issue: This patient has a mechanical mitral valve. DOACs (apixaban) are contraindicated in mechanical valves - the RE-ALIGN trial showed increased thromboembolism and bleeding with dabigatran, and guidelines require a vitamin K antagonist (warfarin) for mechanical valves. This must be corrected regardless of the procedure; apixaban should be stopped and warfarin started with INR target (typically 2.5–3.5 for mitral position, per valve type). Bridging: For most procedures, including colonoscopy with possible polypectomy, bridging is generally not recommended for AF - the BRIDGE trial showed non-inferiority of no bridging with less bleeding. Bridging is reserved for high thrombotic risk (mechanical valve, recent VTE, CHA2DS2-VASc very high with prior stroke). This patient's mechanical valve does raise thrombotic risk, so bridging may be considered, but the prior GI bleed argues for caution. The decision must weigh valve thrombosis risk against bleeding.
2. Outline a peri-procedural plan, including timing of hold, bridging consideration, and restart, accounting for the GI bleed history.
Read the worked answer
1. Fix the anticoagulant first: transition from apixaban to warfarin (mechanical valve requires VKA). This takes days; if the procedure is in 5 days, coordinate with cardiology - do not simply proceed on apixaban. 2. Hold timing: For warfarin, stop ~5 days before to allow INR to normalize (check INR 1–2 days pre-procedure; proceed if INR < 1.5). For apixaban (if still on it), hold 48 h (CrCl 55) before a high-bleeding-risk procedure. 3. Bridging: Given mechanical mitral valve (high thrombotic risk), therapeutic LMWH bridging is reasonable - start when INR falls below therapeutic range, stop ~24 h before procedure. But weigh the prior GI bleed; involve cardiology and GI. For AF alone, no bridging. 4. Procedure: Colonoscopy with possible polypectomy is intermediate-high bleeding risk; discuss with GI whether polypectomy can be deferred or done with cold snare to reduce bleeding. 5. Restart: Resume anticoagulation when hemostasis is secure - typically 24–48 h after polypectomy (longer if high-risk bleeding). Restart warfarin with LMWH bridge until INR therapeutic. 6. Monitoring: Post-procedure CBC, signs of GI bleeding, and INR. Educate patient that 'full blood thinning' throughout is not safe and that the mechanical valve mandates warfarin, not apixaban.